wet macula degeneration research hub

A Phase 3, Randomized, Double-Blind, Parallel Group, Multicenter Study to Compare Efficacy, Safety, Pharmacokinetics, and Immunogenicity of BP05 Versus EU-Approved Lucentis® in Patients with Wet (Neovascular) Age-Related Macular Degeneration

This study is testing a new version of an eye medicine, ranibizumab (like Lucentis), for wet age-related macular degeneration. Researchers want to see if the new version works as well and is as safe as the original to help people see better.